ITS 2012 Report – Immunosuppression: What’s to come? Immunosuppression in the pipeline
by Maria Dalby – Efforts continue to develop new anti-rejection agents that are as effective as the calcineurin inhibitors (CNI) but without the debilitating side effects.

